<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin T McVary, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael P O'Leary, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H973951424"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of glandular epithelial tissue, smooth muscle, and connective tissue within the prostatic transition zone. BPH is ubiquitous in the aging male, with worldwide autopsy-proven histological prevalence starting at age 40 to 45 years, reaching 60 percent at age 60, and 80 percent at age 80 [<a href="#rid1">1</a>].</p><p>BPH can be asymptomatic, in which case it does not require treatment. However, BPH may lead to an enlargement of the prostate (benign prostatic enlargement [BPE]) and result in lower urinary tract symptoms (LUTS) due to obstruction at the level of the bladder neck.</p><p>LUTS can be caused by a variety of conditions. In the discussion below, LUTS/BPH will be used to indicate LUTS attributed to BPH, in accordance with the American Urological Association (AUA) BPH clinical <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Fbenign-prostatic-hyperplasia-%28bph%29-guideline&amp;token=04usxcqhVrf3qk6zmtBNw2IQSOxuXCVn6umAr4HwqNVl5h%2Fiq5BhAWIpg5yxwwnKE%2FzUochFYAxz39ZGD8tyd33uxfcJwRrACOPqZFXDt7yCQkwps0IBlf0sOFPsTW9a&amp;TOPIC_ID=6889" target="_blank">guidelines</a>. This topic will review the clinical manifestations and diagnostic evaluation of LUTS/BPH.</p><p>The epidemiology and pathophysiology of BPH, medical and surgical treatment of BPH, incontinence, other causes of LUTS, and nocturia are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6890.html" rel="external">"Epidemiology and pathophysiology of benign prostatic hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8093.html" rel="external">"Surgical treatment of benign prostatic hyperplasia (BPH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14611.html" rel="external">"Urinary incontinence in men"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1355999431"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The acronym BPH (benign prostatic hyperplasia) is often incorrectly assumed to represent benign prostatic hypertrophy, which is an archaic term describing an increase in cell size rather than cell number. BPH results in benign prostatic enlargement (BPE) in some but not all men. This enlargement can, in turn, lead to benign prostatic obstruction (BPO) and bladder outlet obstruction (BOO). While BPH alone does not require treatment, BPE and BPO are often associated with lower urinary tract symptoms (LUTS), which may require treatment.</p><p class="headingAnchor" id="H2472854139"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3176590089"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Benign prostatic hyperplasia (BPH) can be asymptomatic, and the correlation between symptoms and the presence of prostatic enlargement on physical examination or transrectal ultrasonographic assessment is poor.</p><p>When symptomatic, BPH presents with lower urinary tract symptoms (LUTS). Typical manifestations of LUTS/BPH include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Storage (irritative) symptoms – Urinary frequency, urgency, nocturia and incontinence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Voiding symptoms – Slow urinary stream, straining to void, urinary intermittency (stream starting and stopping during micturition) or hesitancy, splitting of the voiding stream, and terminal dribbling</p><p></p><p>Storage symptoms are often more bothersome than voiding symptoms. Symptom severity (most often graded as mild, moderate, or severe) motivates patients to seek BPH-related treatment [<a href="#rid3">3</a>].</p><p>Physical examination findings include a non-tender, enlarged prostate on digital rectal examination (DRE). The size of the prostate on examination does not correlate well with symptom severity.</p><p>There are no typical laboratory or imaging findings, except that BPH is associated with higher levels of prostate-specific antigen (PSA), produced by benign prostatic tissue.</p><p class="headingAnchor" id="H1243297543"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Symptoms tend to progress gradually over a period of years, especially in older patients; however, they may improve spontaneously in a minority of patients [<a href="#rid4">4-8</a>].</p><p>The natural history of LUTS/BPH progression was described in the Health Professionals Follow-up Study [<a href="#rid4">4</a>]. In this cohort of 9628 men who initially reported moderate LUTS, about one-quarter progressed to severe LUTS over a mean follow-up of 5.9 years, and progression rates rose steeply as men aged.</p><p class="headingAnchor" id="H2320148734"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Potential complications of untreated BPH include acute urinary retention. In addition, chronic obstruction and failure to completely empty the bladder of urine can increase the risk of urinary tract infections (UTIs), bladder stones, formation of bladder diverticuli, and renal damage.</p><p>BPH is not a risk factor for prostate cancer. BPH occurs primarily in the central or transitional zone of the prostate, whereas prostate cancer originates primarily in the peripheral part of the gland. An analysis from the placebo arm of the Prostate Cancer Prevention Trial, where routine biopsies were performed, did not find an association between BPH and prostate cancer [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2344194260"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Many other urologic conditions can present with lower urinary tract symptoms (LUTS). Before concluding that LUTS is related to benign prostatic hyperplasia (BPH), other disorders that can cause these symptoms should be excluded by history, physical examination, and selected laboratory and urologic tests. (See <a class="local">'Evaluation'</a> below.)</p><p>Other causes of LUTS are described in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males"</a> and  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Etiologies of LUTS'</a>.)</p><p>Briefly, other causes include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urologic causes of obstruction </strong>–<strong> </strong>Urethral stricture, bladder neck contracture, and prostate cancer. (See  <a class="medical medical_review" href="/d/html/15175.html" rel="external">"Strictures of the adult male urethra", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/6939.html" rel="external">"Clinical presentation and diagnosis of prostate cancer", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other urologic conditions</strong> – Urinary infections and bladder cancer. (See  <a class="medical medical_review" href="/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/8062.html" rel="external">"Acute bacterial prostatitis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-urologic conditions</strong> – Other medical conditions can either coexist with BPH causing worsening of urologic symptoms, or mimic BPH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular disease – Heart failure, peripheral vascular disease, or cardiac dysfunction associated with peripheral edema may worsen LUTS due to fluid shifts inducing diuresis [<a href="#rid10">10</a>]. Diuretic use can also cause or exacerbate urinary symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic disease – Patients with Parkinson disease or a history of stroke frequently develop voiding dysfunction. Normal micturition requires a complex interplay of the bladder outlet, bladder, and regulatory spinal cord centers, and neurologic events may affect detrusor function and stability. Neurologic conditions may add to the complexity of diagnosis and affect therapeutic options.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endocrine disease – Longstanding, poorly controlled diabetes mellitus leads to decreased bladder sensation, decreased detrusor contractility, and incomplete bladder emptying. Furthermore, increased filtration of glucose in the urine leads to an osmotic diuresis and obligate polyuria, thereby worsening LUTS due to increased urine production. Recognizing this common relationship in LUTS is critical to controlling symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polydipsia – the obligate diuresis from polydipsia may cause urinary symptoms which mimic those of LUTS/BPH. Information about the fluid type and timing of intake relative to symptom onset, the use of a voiding diary, and the lack of obstructive symptoms are helpful in uncovering this relationship.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nocturnal polyuria – Nocturnal polyuria is the leading cause of nocturia, due to the overproduction of urine by the kidneys at night thought to be due to alterations in circulating antidiuretic hormone (ADH or vasopressin) [<a href="#rid11">11,12</a>]. Nocturnal polyuria occurs when &gt;33 percent of the daily urine output is expelled during nighttime hours. The presence of nocturnal polyuria should incite further evaluation for secondary causes. (See  <a class="medical medical_review" href="/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults", section on 'Nocturnal polyuria'</a>.)</p><p></p><p class="headingAnchor" id="H492224874"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) should include a detailed medical history and focused physical examination, which should include a brief neurologic screen, abdominal examination, and genitourinary examination including digital rectal examination (DRE). A small number of laboratory tests are needed to exclude other etiologies.</p><p>The specific goals for the patient should be defined as part of the evaluation. If symptoms are not significantly bothersome or not impacting the patient’s health, or if the patient does not want treatment, no further evaluation is recommended. This approach is recommended by the American Urological Association (AUA) BPH clinical guidelines [<a href="#rid13">13,14</a>] and is a priority of the AUA Choosing Wisely Program [<a href="#rid15">15</a>]. Such patients are unlikely to experience significant health problems in the future due to their condition and can be seen again if necessary.</p><p class="headingAnchor" id="H419838074"><span class="h2">History</span><span class="headingEndMark"> — </span>The history should include evaluation of storage (irritative) symptoms (frequency, urgency, and nocturia) and voiding symptoms (slow or decreased force urinary stream, straining to void, intermittency, hesitancy, splitting of the voiding stream), and post-void dribbling. This information is useful to estimate the impact and severity of initial symptoms.</p><p>Symptoms of hematuria, incontinence, or urinary retention should prompt urology referral. (See <a class="local">'Indications for urology referral'</a> below.)</p><p>Other historical features to elicit include:</p><p class="bulletIndent1"><span class="glyph">●</span>History of urethral trauma, urethritis, or urethral instrumentation that could lead to urethral stricture</p><p class="bulletIndent1"><span class="glyph">●</span>Gross hematuria or pain in the bladder region, which may be suggestive of a bladder calculi or cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying neurologic disease, which might indicate a neurogenic bladder</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking, which is a risk factor for bladder cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with drugs or over-the-counter agents that can impair bladder contractility (eg, anticholinergic agents) or increase outflow resistance (eg, sympathomimetic agents)</p><p class="bulletIndent1"><span class="glyph">●</span>The temporal relationship between the onset and severity of LUTS and medication use (ie, diuretics for hypertension or congestive heart failure)</p><p></p><p>A detailed description of the initial evaluation of a patient with LUTS is provided separately. (See  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Patient evaluation'</a>.)</p><p class="headingAnchor" id="H3908546461"><span class="h3">Voiding diary</span><span class="headingEndMark"> — </span>A well-kept voiding diary or frequency-volume chart is usually obtained in patients who have nocturia as a predominant symptom, but it can be useful in other patients as well. It can provide information on the patient’s total daily voided volume, daily urinary frequency, nocturnal fraction of voiding urine, and functional bladder capacity. It also provides information on fluid intake, incontinent episodes, use of incontinence pads, and/or defecation frequency. Data are typically recorded for three days to create a more representative sample of typical fluid management [<a href="#rid16">16</a>]. Frequency-volume charts are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults", section on 'Frequency-volume chart'</a>.)</p><p>In patients with nocturia, the voiding diary can provide evidence of nocturnal polyuria, which occurs when &gt;33 percent of the daily urine output is expelled during nighttime hours. Nocturnal polyuria should prompt a search for secondary causes and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults", section on 'Nocturnal polyuria'</a>.)</p><p class="headingAnchor" id="H2170981475"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include DRE in addition to evaluation of the abdomen, pelvis, perineum. A motor and sensory evaluation of the pelvis and lower limbs should be performed. Given the complexity of the motor and neurologic interplay involved in pelvic health and bladder maintenance, any abnormal finding should prompt further inquiry. A more extensive neurologic examination is indicated for patients with possible neurogenic lower urinary tract dysfunction.</p><p>DRE should be performed to estimate prostate size. A normal prostate is approximately the size of a walnut (between 7 to 16 grams, with an average of 11 grams) and firm and nontender. Although DRE is not a precise tool for measuring prostate volume [<a href="#rid17">17-19</a>], serial exams are useful to follow prostate size, and the examination can identify other abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span>An exquisitely tender prostate gland may reflect the presence of prostatitis</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of asymmetry or nodules raises suspicion for malignancy (see  <a class="medical medical_review" href="/d/html/6939.html" rel="external">"Clinical presentation and diagnosis of prostate cancer"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of decreased sphincter tone or absence of perineal sensation may suggest a neurologic etiology</p><p></p><p class="headingAnchor" id="H2136296569"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>We obtain urinalysis in all patients being evaluated for BPH/LUTS. The purpose is to identify pyuria, glucosuria, proteinuria, ketonuria, or bacteriuria, which may be signs of alternative diagnoses and thus warrant further evaluation. Although mild hematuria may occur with BPH, the finding of hematuria requires further evaluation for other genitourinary disorders such as cancer of the prostate or bladder, especially in older men. (See  <a class="medical medical_review" href="/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults", section on 'Initial evaluation'</a>.)</p><p>Other studies are not performed routinely but may be useful in certain circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>A urine culture is not needed unless there is other evidence to suggest a urinary tract infection (UTI; ie, dysuria in the setting of pyuria or bacteriuria on urinalysis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine is not needed unless there is evidence to suggest renal impairment (ie, high post-void residual [PVR]) (see <a class="local">'Post-void residual volume measurement'</a> below). A high serum creatinine may be the result of bladder outlet obstruction (BOO) or underlying renal disease. If the serum creatinine concentration is high, renal ultrasonography is indicated to assess for the presence of upper-tract hydronephrosis. (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prostate-specific antigen (PSA) testing is not needed for diagnosis but can be used as a proxy for prostate volume when considering the use of a 5-alpha reductase inhibitor (5ARI). These medications are only useful in men whose prostates are above 35 grams, which correlates with a PSA &gt;1.5 ng/mL [<a href="#rid20">20,21</a>]. In addition, a PSA should be measured prior to initiation of treatment with 5ARI, as such treatment may lower PSA levels (typically by 0.5 ng/mL) and influence future prostate cancer screening [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/7567.html" rel="external">"Screening for prostate cancer", section on 'Correction for 5-alpha reductase inhibitor'</a>.)</p><p></p><p class="bulletIndent1">The use of PSA testing for prostate cancer screening is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7567.html" rel="external">"Screening for prostate cancer", section on 'Screening with prostate-specific antigen'</a>.)</p><p></p><p>The routine use of urine cytology in the setting of LUTS and a normal urinalysis should be avoided.</p><p class="headingAnchor" id="H2596743710"><span class="h2">Symptom questionnaires</span><span class="headingEndMark"> — </span>Validated questionnaires should be utilized to measure symptom severity, symptom bother and to document response to medical or surgical therapies. The most commonly used are the AUA Symptom Index (AUA-SI) and the International Prostate Symptom Score (IPSS). One of these should be obtained at each visit [<a href="#rid23">23</a>]  (<a class="graphic graphic_table graphicRef57680" href="/d/graphic/57680.html" rel="external">table 1</a>). These indices are described in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'International Prostate Symptom Score'</a>.)</p><p class="headingAnchor" id="H4218209217"><span class="h2">Post-void residual volume measurement</span><span class="headingEndMark"> — </span>We obtain a measurement of PVR volume in all patients presenting with LUTS/BPH symptoms to evaluate for retention as recommended by expert groups [<a href="#rid13">13,24</a>]. The PVR can be measured with the aid of a bedside “bladder scanner,” which utilizes ultrasonography to estimate the bladder’s volume, or by use of a straight catheter following the conclusion of a spontaneous void. Bladder palpation is not a reliable method for estimating PVR.</p><p>Moderate to severe LUTS is associated with an increased incidence of acute urinary retention [<a href="#rid25">25</a>]. Normal men have less than 12 mL of residual urine, but most urologists are not concerned unless the PVR volume is greater than 250 mL. Management of acute urinary retention is discussed separately. (See  <a class="medical medical_review" href="/d/html/6883.html" rel="external">"Acute urinary retention"</a>.)</p><p>There is significant interpersonal variability in PVR measurements, and their greatest value is in changes over time. Increasing PVR may indicate treatment failure or provide indication for surgical intervention. A high baseline PVR indicates a higher likelihood of symptomatic deterioration over time [<a href="#rid20">20,26</a>].</p><p class="headingAnchor" id="H1129741609"><span class="h2">Additional tests for selected patients</span></p><p class="headingAnchor" id="H113946780"><span class="h3">Prostate imaging</span><span class="headingEndMark"> — </span>Transrectal ultrasound is not needed for diagnosis. It is indicated only when the treatment choice of LUTS/BPH is dependent on total prostate volume, as in the use of 5ARIs, or in the choice of certain surgical techniques. It is important to remember that size of the prostate gland does not correlate with the degree of obstruction nor with the presence or severity of LUTS.</p><p>The routine use of computed tomography (CT) or magnetic resonance imaging (MRI) for the sole purpose of LUTS/BPH is discouraged, although the repurposing of cross sectional and mid-sagittal images done for other indications can be useful when the treatment choice of LUTS/BPH is dependent on total prostate volume [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3142755441"><span class="h3">Cystoscopy</span><span class="headingEndMark"> — </span>Cystoscopy or, more correctly stated, urethrocystoscopy is not needed in the routine assessment of LUTS/BPH [<a href="#rid22">22</a>]. It should be considered in men with a history suggestive of a urethral stricture or bladder neck contracture. In addition, urologists also routinely perform urethrocystoscopy to assist in planning surgical treatment of men with BPH.</p><p class="headingAnchor" id="H3574449486"><span class="h3">Dynamic testing</span><span class="headingEndMark"> — </span>Additional urodynamic tests, which are typically performed by urologists, can be useful adjuncts in the evaluation of LUTS in some patients. Uroflowmetry is an office-based procedure that can help support the diagnosis of BPH by documenting obstruction; flow rates of &lt;10 mL/s have shown a specificity of 70 percent, a positive predictive value of 70 percent, and a sensitivity of 47 percent for obstruction [<a href="#rid27">27</a>]. If the patient's condition is not suggestive of obstruction (eg, peak urinary flow [Q<sub>max</sub>] &gt;10 mL/sec), pressure flow studies (PFS), which are invasive (requiring use of a small gauge urodynamic catheter) but more conclusive as to the cause of the symptoms, should be considered. PFS are useful in such cases because empiric interventions are at risk of failure in the absence of obstruction. PFS can also be used in the evaluation of patients whose clinical manifestations are atypical or when there is reason to suspect an alternative diagnosis (ie, neurogenic bladder from Parkinsonism). The use of these tests in the evaluation of LUTS are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Uroflowmetry'</a> and  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Pressure-flow studies and urodynamics'</a>.)</p><p class="headingAnchor" id="H674004855"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) is established by the presence of storage, voiding, and/or irritative urinary symptoms in the absence of history, examination or laboratory findings suggesting of non-BPH causes of LUTS. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>The diagnosis does not require histologic confirmation. A prostate biopsy is only warranted if there is concern about prostate cancer such as an asymmetric or nodular gland on digital rectal examination (DRE) or an increased or rising prostate-specific antigen (PSA) level.</p><p class="headingAnchor" id="H1210921794"><span class="h1">INDICATIONS FOR UROLOGY REFERRAL</span><span class="headingEndMark"> — </span>Referral to a urological specialist may be appropriate for patients with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe symptoms or pain</p><p class="bulletIndent1"><span class="glyph">●</span>Men &lt; 45 years old</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormality on digital rectal examination</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated prostate-specific antigen (PSA)</p><p class="bulletIndent1"><span class="glyph">●</span>Dysuria as a possible symptom of bladder cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Incontinence</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic disease known to impact lower urinary tract symptoms (LUTS)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary retention (post-void residual [PVR] urine volume &gt;250 mL, or a palpable bladder)</p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of other urological disease</p><p></p><p class="headingAnchor" id="H954218421"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15355.html" rel="external">"Patient education: Benign prostatic hyperplasia (enlarged prostate) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4849.html" rel="external">"Patient education: Benign prostatic hyperplasia (BPH) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2918736090"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116802.html" rel="external">"Society guideline links: Benign prostatic hyperplasia"</a>.)</p><p class="headingAnchor" id="H588114168"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most men will develop benign prostatic hyperplasia (BPH), which can be associated with lower urinary tract symptoms (LUTS). The common clinical manifestations of LUTS/BPH include storage symptoms (increased daytime frequency, nocturia, urgency, and urinary incontinence) and voiding symptoms (slow urinary stream, splitting or spraying of the urinary stream, intermittent urinary stream, hesitancy, straining to void). Symptoms vary in severity over time and do not correlate well with prostate size or physiologic abnormalities. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining need for treatment</strong> – It is important to assess the severity and health impact of LUTS suspected to be caused by BPH. Men who have minimally bothersome symptoms generally do not need further evaluation or treatment. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – The presumptive diagnosis of LUTS/BPH is established by the presence of storage and voiding symptoms in the absence of a history suggesting non-BPH causes of LUTS. The presence of a symmetrically enlarged, smooth, non-tender prostate on physical examination supports the diagnosis. (See <a class="local">'History'</a> above and <a class="local">'Physical examination'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Other potential causes of LUTS include urethral stricture, bladder neck contracture, prostate cancer (less common), urinary tract infection (UTI) and acute prostatitis, neurogenic bladder, bladder calculi, and bladder cancer (less common).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of BPH/LUTS is intended to rule out other potential causes. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males", section on 'Patient evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest that a urinalysis be obtained in all patients being evaluated for LUTS/BPH. Abnormalities (eg, hematuria, pyuria, glycosuria) suggest potential alternative diagnoses that warrant further evaluation. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain a measurement of post-void residual (PVR) volume in all patients presenting with LUTS/BPH symptoms to evaluate for retention. The PVR can be measured with the aid of a bedside “bladder scanner,” which utilizes ultrasonography to estimate the bladder’s volume, or by use of a straight catheter following the conclusion of a spontaneous void. (See <a class="local">'Post-void residual volume measurement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Men with a predominant symptom of nocturia should complete a voiding diary to evaluate for nocturnal polyuria (&gt;33 percent of the daily urine output is expelled during nighttime hours). Nocturnal polyuria should prompt a search for secondary causes beyond BPH/LUTS. (See <a class="local">'Voiding diary'</a> above and  <a class="medical medical_review" href="/d/html/6877.html" rel="external">"Nocturia: Clinical presentation, evaluation, and management in adults", section on 'Nocturnal polyuria'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of BPH does not require histologic confirmation, and prostate biopsy is only warranted if there is a specific concern about prostate cancer. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom assessment and monitoring</strong> – The American Urologic Association/International Prostate Symptom Score (AUA/IPSS)  (<a class="graphic graphic_table graphicRef57680" href="/d/graphic/57680.html" rel="external">table 1</a>) (assessing for frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency) is useful for quantifying and monitoring BPH symptoms. (See <a class="local">'Symptom questionnaires'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for urologic referral</strong> – Men with abnormal digital rectal examinations (DRE), hematuria, severe symptoms or pain, those under 45 years of age, an abnormal PSA, pain with urination (dysuria), a palpable bladder or urinary retention, incontinence, or neurologic disease known to impact LUTS (ie, Parkinsonism) should be referred to a urologist. (See <a class="local">'Indications for urology referral'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474.</a></li><li><a class="nounderline abstract_t">Welliver C, Sulaver R, Whittington A, et al. Analyzing Why Men Seek Treatment for Lower Urinary Tract Symptoms and Factors Associated With Nonimprovement. Urology 2015; 86:862.</a></li><li><a class="nounderline abstract_t">O'Leary MP. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 2000; 56:7.</a></li><li><a class="nounderline abstract_t">Platz EA, Joshu CE, Mondul AM, et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 188:496.</a></li><li><a class="nounderline abstract_t">Martin S, Lange K, Haren MT, et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014; 191:130.</a></li><li><a class="nounderline abstract_t">Marshall LM, Holton KF, Parsons JK, et al. Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men. Prostate Cancer Prostatic Dis 2014; 17:265.</a></li><li><a class="nounderline abstract_t">Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3:1.</a></li><li><a class="nounderline abstract_t">Maserejian NN, Kupelian V, Miyasato G, et al. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol 2012; 188:490.</a></li><li><a class="nounderline abstract_t">Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173:1419.</a></li><li><a class="nounderline abstract_t">Hoshiyama F, Hirayama A, Tanaka M, et al. The impact of obstructive sleep apnea syndrome on nocturnal urine production in older men with nocturia. Urology 2014; 84:892.</a></li><li><a class="nounderline abstract_t">Weiss JP, van Kerrebroeck PE, Klein BM, Nørgaard JP. Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol 2011; 186:1358.</a></li><li><a class="nounderline abstract_t">Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:737.</a></li><li><a class="nounderline abstract_t">Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol 2018; 200:612.</a></li><li><a class="nounderline abstract_t">Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol 2021; 206:806.</a></li><li class="breakAll">American Urological Association. Fifteen things physicians and patients should question. https://www.choosingwisely.org/societies/american-urological-association/ (Accessed on July 03, 2019).</li><li><a class="nounderline abstract_t">Yap TL, Cromwell DC, Emberton M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int 2007; 99:9.</a></li><li><a class="nounderline abstract_t">Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998; 51:19.</a></li><li><a class="nounderline abstract_t">Pinsky PF, Kramer BS, Crawford ED, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006; 68:352.</a></li><li><a class="nounderline abstract_t">Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004; 46:753.</a></li><li><a class="nounderline abstract_t">McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.</a></li><li><a class="nounderline abstract_t">Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581.</a></li><li><a class="nounderline abstract_t">McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793.</a></li><li><a class="nounderline abstract_t">Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.</a></li><li><a class="nounderline abstract_t">Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015; 67:1099.</a></li><li><a class="nounderline abstract_t">Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173:1256.</a></li><li><a class="nounderline abstract_t">Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006; 97 Suppl 2:7.</a></li><li><a class="nounderline abstract_t">Reynard JM, Yang Q, Donovan JL, et al. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82:619.</a></li></ol></div><div id="topicVersionRevision">Topic 6889 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6206240" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The development of human benign prostatic hyperplasia with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299465" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Analyzing Why Men Seek Treatment for Lower Urinary Tract Symptoms and Factors Associated With Nonimprovement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074196" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : LUTS, ED, QOL: alphabet soup or real concerns to aging men?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704110" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23770136" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000909" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689166" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704109" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540324" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096335" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The impact of obstructive sleep apnea syndrome on nocturnal urine production in older men with nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855948" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17131169" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29775639" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34384237" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34384237" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956355" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586592" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Accurate determination of prostate size via digital rectal examination and transrectal ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904451" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548443" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14681504" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10096388" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420124" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Update on AUA guideline on the management of benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279218" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25613154" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758764" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Urologic diseases in America project: benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507046" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Definition of at-risk patients: baseline variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9839573" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
